LUPRON DEPOT 7.5 SIDE EFFECTS
- Generic Name: leuprolide acetate for depot suspension
- Brand Name: Lupron Depot 7.5 mg
- Drug Class: Antineoplastics, GNRH Agonists
SIDE EFFECTS
Clinical Trials
In the majority of patients testosterone levels increased above baseline during the first week, declining thereafter to baseline levels or below by the end of the second week of treatment.
Potential exacerbations of signs and symptoms during the first few weeks of treatment is a concern in patients with vertebral metastases and/or urinary obstruction or hematuria which, if aggravated, may lead to neurological problems such as temporary weakness and/or paresthesia of the lower limbs or worsening of urinary symptoms.
In a clinical trial of LUPRON DEPOT 7.5 mg for 1-month administration, the following adverse reactions were reported in 5% or more of the patients during the initial 24-week treatment period regardless of causality.
LUPRON DEPOT 7.5 mg for 1-Month Administration (N=56)
N | (%) | |
Body as a Whole | ||
General pain | 13 | (23.2) |
Infection | 3 | (5.4) |
Cardiovascular System | ||
Hot flashes/sweats* | 32 | (57.1) |
Digestive System | ||
GI disorders | 8 | (14.3) |
Metabolic and Nutritional Disorders | ||
Edema | 8 | (14.3) |
Nervous System | ||
Libido decreased* | 3 | (5.4) |
Respiratory System | ||
Respiratory disorder | 6 | (10.7) |
Urogenital System | ||
Urinary disorder | 7 | (12.5) |
Impotence* | 3 | (5.4) |
Testicular atrophy* | 3 | (5.4) |
* Due to the expected physiologic effect of decreased testosterone levels. |
In this same study, the following adverse reactions were reported in less than 5% of the patients on LUPRON DEPOT 7.5 mg for 1-month administration.
Body as a Whole –Asthenia, Cellulitis, Fever, Headache, Injection site reaction, Neoplasm;
Cardiovascular System –Angina, Congestive heart failure;
Digestive System –Anorexia, Dysphagia, Eructation, Peptic ulcer;
Hemic and Lymphatic System –Ecchymosis;
Musculoskeletal System –Myalgia;
Nervous System –Agitation, Insomnia/sleep disorders, Neuromuscular disorders;
Respiratory System –Emphysema, Hemoptysis, Lung edema, Sputum increased;
Skin and Appendages –Hair disorder, Skin reaction;
Urogenital System –Balanitis, Breast enlargement, Urinary tract infection.
Laboratory: Abnormalities of certain parameters were observed, but their relationship to drug treatment are difficult to assess in this population. The following were recorded in ≥ 5% of patients at final visit: Decreased albumin, decreased hemoglobin/hematocrit, decreased prostatic acid phosphatase, decreased total protein, decreased urine specific gravity, hyperglycemia, hyperuricemia, increased BUN, increased creatinine, increased liver function tests (AST, LDH), increased phosphorus, increased platelets, increased prostatic acid phosphatase, increased total cholesterol, increased urine specific gravity, leukopenia.
Postmarketing
The following adverse reactions have been identified during postapproval use of LUPRON DEPOT. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
During postmarketing surveillance, which includes other dosage forms and other patient populations, the following adverse events were reported.
Like other drugs in this class, mood swings, including depression, have been reported. There have been very rare reports of suicidal ideation and attempt. Many, but not all, of these patients had a history of depression or other psychiatric illness. Patients should be counseled on the possibility of development or worsening of depression during treatment with LUPRON.
Symptoms consistent with an anaphylactoid or asthmatic process have been rarely (incidence rate of about 0.002%) reported. Rash, urticaria, and photosensitivity reactions have also been reported.
Changes in Bone Density: Decreased bone density has been reported in the medical literature in men who have had orchiectomy or who have been treated with an LH-RH agonist analog. In a clinical trial, 25 men with prostate cancer, 12 of whom had been treated previously with leuprolide acetate for at least six months, underwent bone density studies as a result of pain. The leuprolide-treated group had lower bone density scores than the nontreated control group. It can be anticipated that long periods of medical castration in men will have effects on bone density.
Pituitary apoplexy: During post-marketing surveillance, rare cases of pituitary apoplexy (a clinical syndrome secondary to infarction of the pituitary gland) have been reported after the administration of gonadotropin-releasing hormone agonists. In a majority of these cases, a pituitary adenoma was diagnosed, with a majority of pituitary apoplexy cases occurring within 2 weeks of the first dose, and some within the first hour. In these cases, pituitary apoplexy has presented as sudden headache, vomiting, visual changes, ophthalmoplegia, altered mental status, and sometimes cardiovascular collapse. Immediate medical attention has been required.
Localized reactions including induration and abscess have been reported at the site of injection.
Symptoms consistent with fibromyalgia (eg, joint and muscle pain, headaches, sleep disorders, gastrointestinal distress, and shortness of breath) have been reported individually and collectively.
Cardiovascular System – Hypotension, Myocardial infarction, Pulmonary embolism;
Respiratory, thoracic and mediastinal disorder – Interstitial lung disease;
Hepato-biliary disorder: Serious drug-induced liver injury
Hemic and Lymphatic System – Decreased WBC;
Central/Peripheral Nervous System – Convulsion, Peripheral neuropathy, Spinal fracture/paralysis;
Endocrine System – Diabetes;
Musculoskeletal System – Tenosynovitis-like symptoms;
Urogenital System – Prostate pain.
See other LUPRON DEPOT and LUPRON Injection package inserts for other events reported in women and pediatric populations.
SRC: NLM .